Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04764630 · ClinicalTrials.gov registry record · Phase 1
Clinical Study to Investigate the Pharmacokinetics of Multiple Repeated Doses of Intranasal Naloxone
A Phase 1 study, sponsored by Food and Drug Administration (FDA).
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT04764630 is a Phase 1 study that has completed, run by Food and Drug Administration (FDA). The registered enrollment target is 21 participants.
The verdict
NCT04764630, a Phase 1 study, has completed, sponsored by Food and Drug Administration (FDA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
Intranasal (IN) naloxone is available as 2 mg or 4 mg dose with the indication to re-administer additional doses every 2 to 3 minutes (using alternating nostrils) if needed until emergency medical assistance arrives. The 4 mg dose is distributed in packages of two nasal sprays (1 dose per nasal spray), but additional doses can be administered if needed and available. While the pharmacokinetics of IN naloxone have been determined following administration of a 4 mg dose in each nostril concurrently, the pharmacokinetics have not been determined following multiple doses when there is a 2-3 minute delay between doses and when doses are re-administered to the same nostril. Obtaining data with repeat dosing will inform if and how fast naloxone plasma concentrations can be reached to be able to reverse highly-potent opioid overdoses. This study will be a randomized, unblinded, three-way crossover study to determine naloxone plasma concentration after administration of multiple doses: A. Four 4 mg IN naloxone doses (1 dose every 2.5 minutes) B. Four 4 mg IN naloxone doses (2 doses every 2.5 minutes) C. Two 4 mg IN naloxone doses (1 dose every 2.5 minutes)
Interventions
- DRUG Four naloxone nasal spray doses (1 every 2.5 min)
- DRUG Four naloxone nasal spray doses (2 every 2.5 min)
- DRUG Two naloxone nasal spray doses (1 every 2.5 min)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2021-03-01 |
| Est. Completion | 2021-03-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04764630
The ClinicalTrials.gov registry entry for NCT04764630 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Food and Drug Administration (FDA), which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Four naloxone nasal spray doses (1 every 2.5 min) is the first listed.
NCT04764630 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04764630 about?
NCT04764630 is a clinical study titled "Clinical Study to Investigate the Pharmacokinetics of Multiple Repeated Doses of Intranasal Naloxone". Intranasal (IN) naloxone is available as 2 mg or 4 mg dose with the indication to re-administer additional doses every 2 to 3 minutes (using alternating nostrils) if needed until emergency medical assistance arrives. The 4 mg dose is distributed in packages of two nasal sprays (1 dose per nasal spra...
What is the current status of trial NCT04764630?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2021-03-01. Estimated completion is 2021-03-20.
What interventions are being tested in trial NCT04764630?
The interventions under investigation include: Four naloxone nasal spray doses (1 every 2.5 min) (DRUG), Four naloxone nasal spray doses (2 every 2.5 min) (DRUG), Two naloxone nasal spray doses (1 every 2.5 min) (DRUG).
Who is sponsoring clinical trial NCT04764630?
This trial is sponsored by Food and Drug Administration (FDA), which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.